2017, Number 4
Combination treatment with solifenacin and mirabegron: An alternative in patients with overactive bladder
PDF size: 210.43 Kb.
Text ExtractionNo abstract,
de Greef-van der Sandt I, Newgreen D, Schaddelee M, Dorrepaal C, et al. A quantitative benefit-risk assessment approach to improve decision making in drug development: Application of a multicriteria decision analysis model in the development of combination therapy for overactive bladder. Clin Pharmacol Ther. 2016;99:442-51.
Drake MJ, Chapple C, Esen AA, Athanasiou S, Cambronero J, Mitcheson D, et al. Efficacy and Safety of Mirabegron Addon Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE). Eur Urol. 2016;70:136-45.